HOME >> BIOLOGY >> NEWS
Targeted genetics presents promising data from cystic fibrosis clinical trial

Studies suggest that aerosolized tgAAV-CF is safe, well tolerated, and efficiently delivered to the lung

Seattle, WA-June 5, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) presented data from its Phase I clinical trial of an aerosol formulation of tgAAV-CF, the Company's gene therapy product for the treatment of cystic fibrosis (CF). Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented the data in an abstract titled "A Phase I Study of Aerosolized Administration of tgAAV-CF to CF patients with Mild Lung Disease" this weekend at the American Society of Gene Therapy Third Annual Meeting in Denver, Colorado.

The Phase I dose-escalation study evaluated the safety and tolerability of tgAAV-CF delivered via nebulizer to 12 patients age 19-41 (median age 29) with mild CF lung disease. All patients in the study had FEV1 levels (a standard measure of lung function) at least 60% of normal. Doses of 1010, 1011, 1012 and 1013 DNAse Resistant Particles (DRP) were evaluated, with each cohort containing three patients. Patients received a single dose of tgAAV-CF and were followed for 90 days post treatment.

"The aerosolized formulation of tgAAV-CF, which we are developing in collaboration with Celltech Group, plc, is well-tolerated in this patient population," said Dr. Reynolds. "Our ability to achieve broad distribution of tgAAV-CF throughout the lungs of these patients validates the aerosol delivery approach we are taking in developing this product. We are on track to initiate a Phase II multi-dose study of aerosolized tgAAV-CF within the next several months. As with the Phase I study presented today, we are working closely with the Cystic Fibrosis Foundation's Therapeutics Development Network (CFF TDN) in designing and conducting the Phase II study. tgAAV-CF is the first gene therapy approach for CF to be selected by the TDN for collaboration and we are proud to be working with the leading physicians
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 ext 229
Noonan/Russo Communications
4-Jun-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
Cached News: